ArticleQuantitative imaging in medicine and surgery2022
Association between quantitative and qualitative image features of contrast-enhanced mammography and molecular subtypes of breast cancer.
Article in Quantitative imaging in medicine and surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- How to optimise breast cancer staging with contrast-enhanced mammography: current evidence and clinical implications.Insights into imaging · 2026Review
- Diagnostic value of contrast-enhanced spectral mammography for breast lesions: qualitative and quantitative analyses.Quantitative imaging in medicine and surgery · 2026Article
- Computed tomography image analysis of cobalt oxide nanoparticles-induced cytopathic effect on Hep-G2 cell lines.RSC advances · 2025Article
- Achieving single-contrast administration for enhanced chest CT and contrast-enhanced spectral mammography without compromising diagnostic quality: a comparative study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Contrast-enhanced mammography for tumor size assessment and detection of multifocal and multicentric disease in breast cancer subtypes.Scientific reports · 2025Article
- Contrast-enhanced mammography-based interpretable machine learning model for the prediction of the molecular subtype breast cancers.BMC medical imaging · 2025Article
- Contrast-enhanced mammography for breast cancer detection and diagnosis with high concentration iodinated contrast medium.Insights into imaging · 2025Article
- Tumor Hypoxia: How Conventional Histology Is Reshaped in Breast Carcinoma.International journal of molecular sciences · 2025Review
- Comparative analysis of diagnostic performance of automatic breast ultrasound and spectral mammography as complementary methods to mammography examination.Polish journal of radiology · 2025Article
- The value of contrast-enhanced energy-spectrum mammography combined with clinical indicators in detecting breast cancer in Breast Imaging Reporting and Data System (BI-RADS) 4 lesions.Quantitative imaging in medicine and surgery · 2024Article
- Novel study on the prediction of BI-RADS 4A positive lesions in mammography using deep learning technology and clinical factors.Quantitative imaging in medicine and surgery · 2024Article
- Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.British journal of cancer · 2024Article
- Magnetic resonance imaging-based prognostic model for subsequent distant metastasis in patients with ipsilateral breast tumor recurrence following breast-conserving surgery.Quantitative imaging in medicine and surgery · 2024Article
- A comprehensive analysis of imaging features and clinical characteristics to differentiate malignant from non-malignant mammographic architectural distortion.Gland surgery · 2024Article
- Clinical and radiological manifestations associated with triple-negative breast cancer in women from northern Peru. A case-control study.Ecancermedicalscience · 2024Article
- Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer.Breast (Edinburgh, Scotland) · 2023Article
- Role of combined clinical-radiomics model based on contrast-enhanced MRI in predicting the malignancy of breast non-mass enhancements without an additional diffusion-weighted imaging sequence.Quantitative imaging in medicine and surgery · 2023Article
- Clinical and pathological features analysis of invasive breast cancer with microcalcification.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe molecular subtype of breast cancer is one of the most important factors affecting patient prognosis. The study aimed to analyze the association between quantitative and qualitative features of contrast-enhanced mammography (CEM) images and breast cancer molecular subtypes.
methodsThis retrospective double-center study included women who underwent CEM between November 2017 and April 2020. Each patient had at least 1 malignant lesion confirmed by pathology. The CEM images were evaluated by 2 radiologists to obtain quantitative and qualitative image features. The molecular subtypes were studied as dichotomous outcomes, including luminal versus non-luminal, human epidermal growth factor receptor (HER2)-enriched versus non-HER2-enriched, and triple-negative breast cancer (TNBC) versus non-TNBC subtypes. The association between the image features and molecular subtypes was analyzed by multivariate logistic regression, with odds ratios (ORs) and 95% confidence intervals (CIs) provided.
resultsA total of 151 patients with 160 malignant lesions were included in the study. For quantitative features, a higher standard deviation of lesion density was associated with non-luminal (OR =0.88, 95% CI: 0.81 to 0.96, P=0.004) and HER2-enriched breast cancers (OR =1.16, 95% CI: 1.04 to 1.28, P=0.006). The relative degree of enhancement (RDE) and contrast-to-noise ratio (CNR) were not associated with molecular subtypes. However, a higher CNR/lesion size (OR =1.06, 95% CI: 1.01 to 1.12, P=0.012) was associated with luminal subtype cancers, and a higher RDE/lesion size (OR =0.94, 95% CI: 0.88 to 1.00, P=0.035) or a higher CNR/lesion size (OR =0.94, 95% CI: 0.88-1.00, P=0.038) was associated with non-TNBCs. For qualitative features, the presence of calcification was associated with HER2-enriched breast cancers (OR =2.91, 95% CI: 1.10 to 7.67, P=0.031). The presence of architectural distortion was associated with luminal cancer (OR =14.50, 95% CI: 1.91 to 110.14, P=0.010) and non-TNBC (OR =0.05, 95% CI: 0.00 to 0.43, P=0.022). Non-mass enhancement (OR =2.78, 95% CI: 1.08 to 7.14, P=0.033) was associated with HER2-enriched breast cancers. An association remained after adjustments for age, breast thickness, and breast density (all adjusted P<0.050).
conclusionsThe quantitative and qualitative imaging features of CEM could contribute to distinguishing breast cancer molecular subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.